We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
Read MoreHide Full Article
Key Takeaways
Quest Diagnostics' Q3 EPS of $2.60 beat estimates and rose 13% year over year.
DGX's revenues grew 15.2% to $2.82B due to a 12.5% rise in test volumes and higher revenue per requisition.
DGX's gross margin expanded 110 bps to 33.7%, and full-year revenue and EPS guidance were raised.
Quest Diagnostics Inc.’s (DGX - Free Report) third-quarter 2025 adjusted earnings per share (EPS) of $2.60 beat the Zacks Consensus Estimate by 3.59%. The metric also exceeded the year-ago adjusted figure by 13%.
Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures. GAAP earnings came in at $2.16 per share, up 8.5% from last year’s comparable figure.
DGX’s Q3 Revenues in Detail
Revenues reported in the third quarter rose 15.2% year over year to $2.82 billion. The metric surpassed the Zacks Consensus Estimate by 3.45%.
Diagnostic Information Services revenues in the quarter were up 13.5% on a year-over-year basis to $2.76 billion. This figure surpassed our model’s projection of $2.64 billion for the third quarter.
Quest Diagnostics Incorporated Price, Consensus and EPS Surprise
Volumes (measured by the number of requisitions) were up 12.5% year over year in the third quarter. Revenue per requisition increased 0.8% year over year.
DGX shares have gained nearly 4.5% in pre-market trading following the earnings report.
DGX’s Q3 Margin Performance
The cost of services during the reported quarter was $1.87 billion, up 11.3% year over year. The gross profit came in at $949 million, rising 17% year over year. The gross margin was 33.7%, up 110 basis points (bps).
SG&A expenses were $501 million in the quarter under review, increasing 11.8% from the third quarter of 2024. The adjusted operating margin of 15.9% represented a 132-bps expansion year over year.
DGX’s Financial Position
Quest Diagnostics exited the third quarter of 2025 with cash and cash equivalents of $432 million compared with $319 million at the end of the second quarter.
The cumulative net cash provided by operating activities at the end of the third quarter of 2025 was $1.42 billion compared with $858 million at the end of the same period last year.
Quest Diagnostics updated its full-year 2025 outlook. Revenues are expected in the range of $10.96 billion-$11.00 billion (previously $10.80-$10.92 billion), which indicates a year-over-year increase of 11%-11.4%. The Zacks Consensus Estimate is pegged at $10.85 billion.
Adjusted EPS is expected in the range of $9.76-$9.84 (earlier $9.63-$9.83). The Zacks Consensus Estimate for the metric is pegged at $9.74.
Our View on DGX Stock
Quest Diagnostics ended the third quarter of 2025 with both earnings and revenues beating estimates. Both metrics increased on a year-over-year basis, highlighting strong demand for the company’s clinical solutions and solid execution of strategy. The expansion of both margins is highly encouraging. Based on the strength of its year-to-date performance, it raised the outlook for the full year.
The quarter marked several highlights, including an agreement with Corewell Health to establish a lab services joint venture in Michigan and the completion of the acquisition of select dialysis testing assets from Fresenius Medical Care. Quest Diagnostics also secured FDA breakthrough device designation for the Haystack MRD test and formed collaborations with Mass General Brigham and Rutgers Cancer Institute to trial Haystack MRD in guiding postoperative therapy decisions.
DGX’s Zacks Rank & Key Picks
Quest Diagnostics currently has a Zacks Rank #3 (Hold).
Phibro Animal Health reported a fourth-quarter fiscal 2025 EPS of 57 cents, which beat the Zacks Consensus Estimate by 9.62%. Net sales of $378.7 million topped the consensus estimate by 4.86%. PAHC currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Phibro has an estimated earnings growth rate of 21.1% in fiscal 2026 compared with the industry’s 12.8%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 27.88%.
Veracyte, sporting a Zacks Rank #1, reported second-quarter 2025 adjusted EPS of 44 cents, which beat the Zacks Consensus Estimate by 41.9%. Revenues of $130.2 million topped the Zacks Consensus Estimate by 7.1%.
VCYT has an estimated earnings growth rate of 19.3% for 2025 compared with the industry’s 12.9%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 242.77%.
Insulet, sporting a Zacks Rank #1, reported a second-quarter 2025 adjusted EPS of $1.17, which outperformed the Zacks Consensus Estimate by 25.81%. Revenues of $649.1 million exceeded the Zacks Consensus Estimate by 5.46%.
PODD has an estimated earnings growth rate of 42.3% for 2025 compared with the industry’s 12.7%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 19.54%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
Key Takeaways
Quest Diagnostics Inc.’s (DGX - Free Report) third-quarter 2025 adjusted earnings per share (EPS) of $2.60 beat the Zacks Consensus Estimate by 3.59%. The metric also exceeded the year-ago adjusted figure by 13%.
Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures. GAAP earnings came in at $2.16 per share, up 8.5% from last year’s comparable figure.
DGX’s Q3 Revenues in Detail
Revenues reported in the third quarter rose 15.2% year over year to $2.82 billion. The metric surpassed the Zacks Consensus Estimate by 3.45%.
Diagnostic Information Services revenues in the quarter were up 13.5% on a year-over-year basis to $2.76 billion. This figure surpassed our model’s projection of $2.64 billion for the third quarter.
Quest Diagnostics Incorporated Price, Consensus and EPS Surprise
Quest Diagnostics Incorporated price-consensus-eps-surprise-chart | Quest Diagnostics Incorporated Quote
Volumes (measured by the number of requisitions) were up 12.5% year over year in the third quarter. Revenue per requisition increased 0.8% year over year.
DGX shares have gained nearly 4.5% in pre-market trading following the earnings report.
DGX’s Q3 Margin Performance
The cost of services during the reported quarter was $1.87 billion, up 11.3% year over year. The gross profit came in at $949 million, rising 17% year over year. The gross margin was 33.7%, up 110 basis points (bps).
SG&A expenses were $501 million in the quarter under review, increasing 11.8% from the third quarter of 2024. The adjusted operating margin of 15.9% represented a 132-bps expansion year over year.
DGX’s Financial Position
Quest Diagnostics exited the third quarter of 2025 with cash and cash equivalents of $432 million compared with $319 million at the end of the second quarter.
The cumulative net cash provided by operating activities at the end of the third quarter of 2025 was $1.42 billion compared with $858 million at the end of the same period last year.
The company has a five-year annualized dividend growth rate of 7.21%.
DGX’s 2025 Guidance
Quest Diagnostics updated its full-year 2025 outlook. Revenues are expected in the range of $10.96 billion-$11.00 billion (previously $10.80-$10.92 billion), which indicates a year-over-year increase of 11%-11.4%. The Zacks Consensus Estimate is pegged at $10.85 billion.
Adjusted EPS is expected in the range of $9.76-$9.84 (earlier $9.63-$9.83). The Zacks Consensus Estimate for the metric is pegged at $9.74.
Our View on DGX Stock
Quest Diagnostics ended the third quarter of 2025 with both earnings and revenues beating estimates. Both metrics increased on a year-over-year basis, highlighting strong demand for the company’s clinical solutions and solid execution of strategy. The expansion of both margins is highly encouraging. Based on the strength of its year-to-date performance, it raised the outlook for the full year.
The quarter marked several highlights, including an agreement with Corewell Health to establish a lab services joint venture in Michigan and the completion of the acquisition of select dialysis testing assets from Fresenius Medical Care. Quest Diagnostics also secured FDA breakthrough device designation for the Haystack MRD test and formed collaborations with Mass General Brigham and Rutgers Cancer Institute to trial Haystack MRD in guiding postoperative therapy decisions.
DGX’s Zacks Rank & Key Picks
Quest Diagnostics currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Veracyte (VCYT - Free Report) and Insulet (PODD - Free Report) .
Phibro Animal Health reported a fourth-quarter fiscal 2025 EPS of 57 cents, which beat the Zacks Consensus Estimate by 9.62%. Net sales of $378.7 million topped the consensus estimate by 4.86%. PAHC currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Phibro has an estimated earnings growth rate of 21.1% in fiscal 2026 compared with the industry’s 12.8%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 27.88%.
Veracyte, sporting a Zacks Rank #1, reported second-quarter 2025 adjusted EPS of 44 cents, which beat the Zacks Consensus Estimate by 41.9%. Revenues of $130.2 million topped the Zacks Consensus Estimate by 7.1%.
VCYT has an estimated earnings growth rate of 19.3% for 2025 compared with the industry’s 12.9%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 242.77%.
Insulet, sporting a Zacks Rank #1, reported a second-quarter 2025 adjusted EPS of $1.17, which outperformed the Zacks Consensus Estimate by 25.81%. Revenues of $649.1 million exceeded the Zacks Consensus Estimate by 5.46%.
PODD has an estimated earnings growth rate of 42.3% for 2025 compared with the industry’s 12.7%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 19.54%.